Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1884-1890
Published online before print June 30, 2005, doi: 10.1161/01.ATV.0000175761.59602.16
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
25/9/1884    most recent
01.ATV.0000175761.59602.16v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chalothorn, D.
Right arrow Articles by Faber, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chalothorn, D.
Right arrow Articles by Faber, J. E.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1884.)
© 2005 American Heart Association, Inc.


Vascular Biology

Heparin-Binding Epidermal Growth Factor–Like Growth Factor, Collateral Vessel Development, and Angiogenesis in Skeletal Muscle Ischemia

Dan Chalothorn; Scott M. Moore; Hua Zhang; Susan W. Sunnarborg; David C. Lee; James E. Faber

From the Departments of Cell and Molecular Physiology (D.C., S.M.M., H.Z., J.E.F.) and Biochemistry (S.W.S., D.C.L.), University of North Carolina, Chapel Hill.

Correspondence to James E. Faber, PhD, Dept of Cell and Molecular Physiology, 103 Mason Farm Rd, 6309 MBRB, CB 7545, University of North Carolina, Chapel Hill, NC 27599-7545. E-mail jefaber{at}med.unc.edu

Objective— Heparin-binding epidermal growth factor–like growth factor (HB-EGF) is a potent mitogen for smooth muscle cells and has been implicated in atherosclerosis, tissue regeneration after ischemia, vascular development, and tumor angiogenesis. We examined the hypothesis that HB-EGF participates in angiogenesis and collateral growth in ischemia.

Methods and Results— During 3 weeks after femoral artery ligation, no attenuation occurred in recovery of hindlimb perfusion or distal saphenous artery flow in HB-EGF–null (HB-EGF–/–) versus wild-type mice. Lumen diameters of remodeled collaterals in gracilis muscle were similar by morphometry (87±8 versus 94±6 µm) and angiography, although medial thickening was reduced. Gastrocnemius muscle underwent comparable angiogenesis (41% and 33% increase in capillary-to-muscle fiber ratio). Renal renin mRNA, arterial pressure, and heart rate during anesthesia or conscious unrestrained conditions were similar between groups. These latter findings validate comparisons of perfusion data and also suggest that differences in arterial pressure and/or renin–angiotensin activity are not masking an otherwise inhibitory effect of HB-EGF absence. Four days after ligation, EGF receptor phosphorylation increased in muscle by 104% in wild-type but by only 30% in HB-EGF–/– mice. This argues against compensation by other EGF receptor ligands.

Conclusion— Our results suggest that HB-EGF is not required for arteriogenesis or angiogenesis in hindlimb ischemia.

We examined whether HB-EGF participates in arteriogenesis and angiogenesis after femoral ligation in HB-EGF-null (–/–) mice. No attenuation occurred in hind-limb perfusion recovery, collateral growth, or angiogenesis. Renin and arterial pressure were unaltered in HB-EGF–/–. Although EGFR phosphorylation was decreased in HB-EGF–/–, HB-EGF is not required for arteriogenesis or angiogenesis.


Key Words: angiogenesis • collateral formation • HB-EGF




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Belmadani, K. Matrougui, C. Kolz, Y. F. Pung, D. Palen, D. J. Prockop, and W. M. Chilian
Amplification of Coronary Arteriogenic Capacity of Multipotent Stromal Cells by Epidermal Growth Factor
Arterioscler. Thromb. Vasc. Biol., June 1, 2009; 29(6): 802 - 808.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. R. Distasi, J. Case, M. A. Ziegler, M. C. Dinauer, M. C. Yoder, L. S. Haneline, M. C. Dalsing, S. J. Miller, C. A. Labarrere, M. P. Murphy, et al.
Suppressed hindlimb perfusion in Rac2-/- and Nox2-/- mice does not result from impaired collateral growth
Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H877 - H886.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Zhang, S. W. Sunnarborg, K. K. McNaughton, T. G. Johns, D. C. Lee, and J. E. Faber
Heparin-Binding Epidermal Growth Factor-Like Growth Factor Signaling in Flow-Induced Arterial Remodeling
Circ. Res., May 23, 2008; 102(10): 1275 - 1285.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
D. Chalothorn, J. A. Clayton, H. Zhang, D. Pomp, and J. E. Faber
Collateral density, remodeling, and VEGF-A expression differ widely between mouse strains
Physiol Genomics, July 18, 2007; 30(2): 179 - 191.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Ryzhov, J. L. McCaleb, A. E. Goldstein, I. Biaggioni, and I. Feoktistov
Role of Adenosine Receptors in the Regulation of Angiogenic Factors and Neovascularization in Hypoxia
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 565 - 572.
[Abstract] [Full Text] [PDF]